factors for the time to first flatus, start of feeding and discharge were analysed (eg, taking promotility agents, such as metoclopramide), but no significant differences were found between the two groups (p=0.375, 0.162, 0.960). Conclusion and relevance Could evidence based medicine lead to an equally satisfying practice? The implementation of the interprofessional team was essential (eg, the core physician team had not participated at the beginning and thus missed many possible cases).
A351 general hospital (PB 6M€). We chose 24 active ingredients (95 different antibiotics) that represent about 1/3 of total hospital antibiotics and 80% of the total antibiotics' budget. We studied their consumption for the years 2011 and 2012 and calculated the costs based on the official drug pricelist and their price after the negotiation. Results: From 2011 to 2012 the discounts gained from each hospital were increased. Price negotiation does not apply in prototype drugs that their companies are only obliged to offer a 5% rebate. Unfortunately, these medications are more expensive, represent 36% of the studied antibiotics' cost and their consumption was increased by 20%. But, the discounts for all the studied off-patent drugs and their generics were from 12.8% till 89.9%. Thus, the total cost saving for them was 33.2% at PAGNI, 26.0% at Evaggelismos and 43.1% at Tzaneio. The total benefit for the pharmaceutical expenditure was 3% for both PAGNI and Evaggelismos, and 6% for Tzaneio. ConClusions: Price negotiation is an effective mean of decreasing the cost of off-patent and generic drugs but newer and expensive drugs get doctors' preference, undermining the Pharmacy's cost-saving effort.
ophthalmology and neurology departments was especially studied. The pharmacoeconomic evaluation was performed using a direct cost comparison analysis, in which MAbs cost is compared (2011-2014) to total drug cost per department, total in-patent drug cost, in-patent antibiotics cost and anti-HIV drug cost. The cost saving of Central Cytostatic Drug Preparation Unit operation for the year 2014 was especially studied. The analysis was performed in Euros (€) and drug cost was based on average hospital prices in Greece (official price lists). Results: Data analysis revealed that MAbs relative cost showed an augmentative trend throughout the study period (from 12.6%, 2008 to 13.45%, 2014). MAbs cost for all studied clinics, with the exception of ophthalmology and hematology departments, showed minor decline. In-patent antibiotics and anti-HIV drugs represented a substantial and ongoing category of cost burden prescribed drugs (from 6.18%, 2011 to 9.98%, 2014 and from 13.04%, 2011 to 21.44%, 2014 respectively). ConClusions: From 2008 to 2012, though a substantial reduce of hospital pharmaceutical expenditure was obtained, due to memorandum obligations, an increase in MAbs consumption was detected (from 12.6% to 13.45%of total drug cost).The average hospital prices for all drugs were reduced for the same period. The total cost saving is mainly due both to generics and off-patent drugs use and drugs' price negotiations supported with an obligated by the Ministry of Health 5% and 6.5 % rebate for in-patent drugs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.